Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ValiBio moves prototype cancer blood test forward

This article was originally published in Clinica

Executive Summary

ValiBio has started a trial of its first prototype Nucleosomics cancer diagnostic, using it to test blood samples from patients who have already been diagnosed with cancer. The subsidiary of ValiRx (London, UK) hopes the trial will determine the diagnostic predictive correlation of the test, and plans to study a wider patient sample if the results are positive. The first test could be launched in the next 15 months, it says. The Nucleosomics test uses standard enzyme-linked immunosorbent assay (ELISA) technology and detects epigenetic histone modifications in blood samples that correspond with a specific cancer. Epigenetics refers to reversible changes in gene expression caused by environmental factors; deregulation of normal epigenetic control mechanisms has been linked to the development and progression of certain tumours. Gosselies, Belgium-based ValiBio hopes its test will be used for the early diagnosis of cancers such as colon and pancreatic, which often do not have obvious symptoms.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel